Half Year 2026 Fresenius SE & Co KGaA Earnings Call Transcript

Aug 5, 2026 / 11:30 AM GMT

Release Date Price: €46.64 (+5.08%)

Transcript

Key Points

Positve

Fresenius SE & Co. KGaA (FSNUY) raised its full-year core EPS growth guidance to 10%-15% at constant currency, reflecting strong first-half performance and improved earnings quality.
The company delivered strong Q2 results with organic revenue growth of 6%, EBIT growth of 10% at constant currency, and an EBIT margin expansion of 60 basis points to 12.3%.
Fresenius Kabi's growth vectors (biopharma, medtech, nutrition) delivered 12% organic growth, with biopharma surging 38% and medtech up 11%, demonstrating scalable and profitable growth.
Helios maintained a resilient EBIT margin of 10.6%, within its structural target range, despite regulatory uncertainties, and the German Gicsa Stabilization Act provides a constructive reimbursement framework for 2027.
The company's balance sheet remains strong with leverage at 2.6x net debt-to-EBITDA, and operating cash flow reached EUR 2.8 billion on a last-12-month basis, supporting strategic flexibility and investment in growth.
Biopharma achieved key regulatory milestones, including FDA approval of rituximab biosimilar and US/EU submission acceptance for vedolizumab, expanding the pipeline and long-term growth potential.

Negative

Fresenius SE & Co. KGaA (FSNUY) faces ongoing pricing pressure in the US pharma market, which partially offset volume growth and contributed to a modest 1% organic revenue growth in the pharma segment.
The Melrose Park manufacturing site received an Official Action Indicated (OAI) status from the FDA, requiring corrective actions, though the company expects no material impact on 2026 production or financials.
Helios Spain's margin performance has shown limited progress over recent years, and the company faces tough comparisons in Q4, particularly in Spain and Germany, due to the expiration of the surcharge for publicly insured patients.
The nutrition business in China remains weak due to a soft economic environment and volume-based procurement effects, with expectations of flat development in the second half and no growth until 2027.
The company anticipates potential headwinds from input costs, including oil prices and feedstock granulates, which could impact margins, though these are already baked into guidance.
Q4 2026 is expected to face difficult year-over-year comparisons due to strong prior-year performance, which may temper earnings growth in the second half.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

FREG.DE - Fresenius SE & Co. KGaA
Half Year 2026 Fresenius SE & Co KGaA Earnings Call
Aug 05, 2026 / 11:30AM GMT

=====================
Conference Call Participants
=====================
* Nick Stone
Fresenius SE & Co. KGaA - Senior Vice President Investor Relations, Head of Investor Relations
* Michael Sen
Fresenius SE & Co. KGaA - Chairman of the Management Board
* Sara Hennicken
Fresenius SE & Co. KGaA - Chief Financial Officer, Member of the Management Board
* Hugo Solvet
Exane Bnp Paribas - Analyst
* Hassan Al-Wakeel
Barclays Services Corp - Analyst
* Oliver Reinberg
Kepler Cheuvreux SA - Analyst
* Veronika Dubajova
Citibank Cameroon SA (Douala Branch) - Analyst
* Oliver Metzger
Oddo BHF SCA - Analyst
* James Vane-Tempest
Jefferies LLC - Equity Analyst
* Aisyah Noor
Morgan Stanley & Co Ltd - Equity Analyst
* Anna Ractliffe
Bofa Merrill

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.